5 April 2017
Further to LivaNova Plc’s (“LivaNova”) announcement on 23 February 2017 that it had made an application (i) to the UK Financial Conduct Authority for the cancellation of the standard listing of LivaNova’s ordinary shares of £1 per share (ISIN: GB00BYMT0J19) (the “Shares”) on the Official List of the UK Listing Authority and (ii) to the London Stock Exchange plc (the “LSE”) to cancel the admission to trading of the Shares on the Main Market of the LSE (together, the “Cancellation”), with effect from and including 5 April 2017, LivaNova hereby announces that the Cancellation has taken effect at 8:00 a.m. BST today.
The listing of LivaNova’s Shares on NASDAQ remains unaffected.
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs approximately 4,600 employees.
LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.livanova.com, or contact:
Tel: +44 (0)203 325 0662
VP – Investor Relations
Tel: +1(281) 228-7441